Evidence map›Paper›PMID 40436644›Full record

ReviewJournal of Zhejiang University. Science. B2025

Unmet needs of patients with intravascular large B-cell lymphoma: three case reports and a literature review.

Xian Li, Ru Luo, Jiaming Xu, Xueli Jin, Weiqin Wang, Xibin Xiao, Wenbin Qian

Abstract readCase ReportsReview
In one paragraph

Review in Journal of Zhejiang University. Science. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xian LiDepartment of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Ru LuoDepartment of Pathology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Jiaming XuDepartment of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Xueli JinDepartment of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Weiqin WangDepartment of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Xibin XiaoDepartment of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. xiaoxibinzju@zju.edu.cn.
Wenbin QianDepartment of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. xiaoxibinzju@zju.edu.cn, qianwb@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravascular large B-cell lymphoma (IVLBCL), a rare subtype of non-Hodgkin lymphoma, is classified as an independent subtype of extranodal diffuse large B-cell lymphoma (DLBCL) in the 2008 World Health Organization (WHO) Classification (Turner et al., 2010). The 5th edition of the World Health Organization (WHO 2022) classification of hematolymphoid tumors retains this subtype (Alaggio et al., 2022). IVLBCL, which is characterized by neoplastic lymphocyte proliferation within the lumen of small blood vessels, tends to invade organs, such as the nervous system, skin, bone marrow (BM), and lung (D'Angelo et al., 2019; Satoh et al., 2019; Vásquez et al., 2019; Fukami et al., 2020).

Indexed as

Lymphoma, Large B-Cell, DiffuseVascular NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumans

Identifiers

PMID40436644
PMCPMC12119180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.